In stage I-III colorectal cancer, a combination of molecular markers, tumor location with the other clinical-pathological variables and microsatellite status may be useful predictors [38].Previous studies have clarified the association of MSI/BRAF combination subgroup on clinical outcomes in CRC, supporting the prognostic role of MSI/BRAF combined detection in CRC [39]. This evidence concerns the gene BRAF and colorectal carcinoma.